In the current issue of the Netherlands Journal of Medicine, inflammatory bowel disease
(IBD) specialists from the Dutch University Medical Centres publish their guidelines for the …

Infliximab is a monoclonal antibody against tumor necrosis factor alpha (TNF-α), which is
approved for the treatment of chronic inflammatory bowel disease (IBD) such as Crohn's …

Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour
necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune …

Infliximab (IFX) has tremendously enriched the therapy of inflammatory bowel diseases
(IBD) and other immune mediated diseases. Although the efficacy of IFX was undoubtedly …

Very recently infliximab--a tumour necrosis factor blocking antibody--was registered as an
important novel immunomodulating therapy for active Crohn's disease in the Netherlands …

In this large series, the investigators evaluated the short-and long-term safety of infliximab in
patients with Crohn's disease. Using pharmacy records, 500 patients with Crohn's disease …

In the evaluation of a new treatment, particularly for a novel agent such as infliximab, there is
a critical requirement to evaluate efficacy and the adverse event profile. Although a clinical …

Objective Antitumor necrosis factor α agents have significantly improved the management of
Crohn's disease (CD), but not all patients benefit from this therapy. We used data from the …

For several decades, physicians have accepted that the quality of life of their patients with
Crohn's disease (CD) was far from optimal throughout long periods of their lives. The …

Infliximab is an effective treatment for active luminal and fistulating Crohn's disease and is
emerging as a treatment for ulcerative colitis. Its use in much of the world is, however, limited …